Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

ophthamologists

  • Home
  •  
  • ophthamologists



  • Most Read
  • Latest Comments
  • Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Nova Eye Medical reports surge in USA sales despite Medicare reimbursement uncertainty
    Nova Eye Medical reports surge in USA sales despite Medicare reimbursement uncertainty
    • News

  • All eyes on PYC as it doses first patient for eye disease trial
    All eyes on PYC as it doses first patient for eye disease trial
    • News

  • Nova’s Glaucoma surgical device iTrack Advance has its eyes set on FDA approval
    Nova’s Glaucoma surgical device iTrack Advance has its eyes set on FDA approval
    • News

  • Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    • News

  • Painchek to launch infant pain assessment app in Europe and APAC
    Painchek to launch infant pain assessment app in Europe and APAC
    • News

  • Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals
    • News

    Nova Eye Health sees immediate sales of glaucoma surgery device following regulatory approvals

    With improvements in allied healthcare, the 134 million people worldwide diagnosed with glaucoma is likely to increase with better diagnostics, but also ensure earlier detection which can be treated sooner as evidenced by medtech company Nova Eye Medical (ASX: EYE) and rising sales of their advanced ophthalmic treatment technologies and devices.  As the developers and

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.